Please ensure Javascript is enabled for purposes of website accessibility

Why Cara Therapeutics Stock Is Crashing Today

By Keith Speights - Apr 29, 2021 at 11:33AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company reported disappointing results from a phase 2 study.

What happened

Shares of Cara Therapeutics (CARA -5.59%) were crashing 43.9% lower as of 11:17 a.m. EDT on Thursday. The big drop came after the company announced results from its phase 2 study evaluating oral Korsuva in treating moderate-to-severe pruritis in patients with atopic dermatitis. 

So what

With the biotech stock falling so heavily today, you'd think that all the results from the phase 2 trial were really bad. That wasn't entirely the case, though.

Man wearing a suit looking at a red line with arrow crashing through the floor

Image source: Getty Images.

The company did report that oral Korsuva didn't meet the primary endpoint of the study -- a statistically significant change from baseline in the weekly mean of the daily 24-hour itch numerical rating scale (NRS) score at week 12 of the treatment period. It also announced that the drug failed to meet the key secondary endpoint of the study -- an improvement from baseline of at least four points in the weekly mean of the daily 24-hour itch NRS score at week 12.

However, Cara said that oral Korsuva did achieve statistically significant improvement in the primary endpoint of the study as early as the first week after dosing. This improvement was sustained through 75% of the treatment period. The company also stated that both primary and key secondary endpoints were met in prespecified analyses in study participants with mild-to-moderate atopic dermatitis.

Now what

Despite the bad news, Cara Therapeutics doesn't think it's the end of the road for oral Korsuva in treating atopic dermatitis. Chief Medical Officer Joana Goncalves said, "We now have a defined patient group and active dose range for Oral KORUSVA in which to design a registration program that we expect to discuss with the FDA in the coming months." 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cara Therapeutics, Inc. Stock Quote
Cara Therapeutics, Inc.
CARA
$8.62 (-5.59%) $0.51

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.